Advanced Breast Cancer Patients Denied Access To Breakthrough Treatment

[News]

National Institute for Health and Clinical Excellence (NICE) issues negative draft decision for Afinitor® (everolimus) The National Institute for Health and Clinical Excellence (NICE) today issued an Appraisal Consultation Document (ACD) recommending that Novartis' life extending advanced breast cancer treatment, Afinitor® (everolimus), should not be available to patients on the NHS...

More... (http://www.medicalnewstoday.com/releases/258029.php)